Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Thomas A Hope^{1

2}, Emily K Bergsland^{3

4}, Murat Fani Bozkurt⁵, Michael Graham⁶, Anthony P Heaney⁷, Ken Herrmann⁵, James R Howe^{4

8}, Matthew H Kulke^{3

4

9}, Pamela L Kunz^{3

4

9}, Josh Mailman¹⁰, Lawrence May¹¹, David C Metz^{4

12}, Corina Millo⁶, Sue O'Dorisio^{6

3

4}, Diane L Reidy-Lagunes^{3

4}, Michael C Soulen^{4

13}, Jonathan R Strosberg^{3

4}

Affiliations

¹ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia thomas.hope@ucsf.edu.
² American College of Radiology, Reston, Virginia.
³ American Society of Clinical Oncology, Alexandria, Virginia.
⁴ North American Neuroendocrine Tumor Society, Albany, New York.
⁵ European Association of Nuclear Medicine, Vienna, Austria.
⁶ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
⁷ Endocrine Society, Washington, DC.
⁸ Society of Surgical Oncology, Rosemont, Illinois.
⁹ National Comprehensive Cancer Network, Fort Washington, Pennsylvania.
¹⁰ NorCal CarciNET, Ripon, California.
¹¹ American College of Physicians, Washington, DC.
¹² American Gastroenterological Association, Bethesda, Maryland; and.
¹³ Society of Interventional Oncology, Washington, DC.

Thomas A Hope et al. J Nucl Med. 2018 Jan.

. 2018 Jan;59(1):66-74.

doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12.

¹ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia thomas.hope@ucsf.edu.
² American College of Radiology, Reston, Virginia.
³ American Society of Clinical Oncology, Alexandria, Virginia.
⁴ North American Neuroendocrine Tumor Society, Albany, New York.
⁵ European Association of Nuclear Medicine, Vienna, Austria.
⁶ Society of Nuclear Medicine and Molecular Imaging, Reston, Virginia.
⁷ Endocrine Society, Washington, DC.
⁸ Society of Surgical Oncology, Rosemont, Illinois.
⁹ National Comprehensive Cancer Network, Fort Washington, Pennsylvania.
¹⁰ NorCal CarciNET, Ripon, California.
¹¹ American College of Physicians, Washington, DC.
¹² American Gastroenterological Association, Bethesda, Maryland; and.
¹³ Society of Interventional Oncology, Washington, DC.

No abstract available

References

1. Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597. - PubMed
1. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. - PMC - PubMed
1. John M, Meyerhof W, Richter D, et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996;38:33–39. - PMC - PubMed
1. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe1]- and [¹²³I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731. - PubMed
1. Bombardieri E, Ambrosini V, Aktolun C, et al. ¹¹¹In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–1448. - PubMed